News/ News/ Oncology Sanofi to acquire Kiadis and NK cell tech for $353 million Richard Staines cancer, cell therapy, Kiadis, M&A, Sanofi 0 Comment Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) Share X Sanofi to acquire Kiadis and NK cell tech for $353 million https://pharmaphorum.com/news/sanofi-to-acquire-kiadis-and-nk-cell-tech-for-353-million/
R&D/ Views & Analysis/ Views and analysis Coronavirus pharma news round-up 21/08/20 Richard Staines artificial intelligence, BioNTech, coronavirus, COVID-19, infectious diseases, Kiadis, Pfizer, Roche, vaccines 0 Comment New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate Share X Coronavirus pharma news round-up 21/08/20 https://pharmaphorum.com/views-and-analysis/coronavirus-pharma-news-round-up-21-08-20/
News/ News/ Oncology/ Top stories Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma Richard Staines Kiadis, multiple myeloma, Sanofi, Sarclisa 0 Comment Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells Share X Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma https://pharmaphorum.com/news/sanofi-to-develop/
artificial intelligence, BioNTech, coronavirus, COVID-19, infectious diseases, Kiadis, Pfizer, Roche, vaccines
0 Comment
